Tianjin, 24 February 2025 - CanSino Biologics Inc (“CanSinoBIO” or “the Company”) is pleased to announce that it has obtained clinical trial approval from the National Medical Products Administration of the People’s Republic of China to initiate a clinical trial for its absorbed diphtheria, tetanus and acellular pertussis (components) (the “DTcP”) Haemophilus Influenzae Type b (Conjugate) (the “Hib”) - Group ACYW135 Meningococcal (Conjugate) (the “MCV4”) combined vaccine (the “DTcP-Hib-MCV4 Combined Vaccine”).

The milestone comes as the Company’s MCV4 Menhycia®, as the first MCV4 vaccine product in China, has secured new drug approval and has been commercialized. Additionally, the DTcP Infant vaccine is in Phase III clinical trials, and the Hib Vaccine is in Phase I clinical trials.

Building upon the accumulated data from these vaccines, CanSinoBIO aims to develop the DTcP-Hib-MCV4 Combined Vaccine, to meet the rising market demand for combined vaccines.

Furthermore, CanSinoBIO is expanding its global innovative vaccine portfolio with its VLP-Polio vaccine, which is currently in Phase Ⅰ/Ⅱ clinical trials in Indonesia. This vaccine also has the potential to become a component of the combined vaccine, further strengthening the Company’s competitive advantage in the market.

CanSinoBIO is dedicated to provide innovative, high-quality and affordable vaccines. With a strong focus on improving public health, the Company leverages advanced technology to create advanced vaccine products that address global health challenges.